JP2022036976A5 - - Google Patents

Download PDF

Info

Publication number
JP2022036976A5
JP2022036976A5 JP2021188305A JP2021188305A JP2022036976A5 JP 2022036976 A5 JP2022036976 A5 JP 2022036976A5 JP 2021188305 A JP2021188305 A JP 2021188305A JP 2021188305 A JP2021188305 A JP 2021188305A JP 2022036976 A5 JP2022036976 A5 JP 2022036976A5
Authority
JP
Japan
Prior art keywords
antigen
car
binding domain
domain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021188305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022036976A (ja
Filing date
Publication date
Priority claimed from JP2017525517A external-priority patent/JP7023708B2/ja
Application filed filed Critical
Publication of JP2022036976A publication Critical patent/JP2022036976A/ja
Publication of JP2022036976A5 publication Critical patent/JP2022036976A5/ja
Pending legal-status Critical Current

Links

JP2021188305A 2014-11-12 2021-11-19 阻害性キメラ抗原受容体 Pending JP2022036976A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462078927P 2014-11-12 2014-11-12
US62/078,927 2014-11-12
US201462081960P 2014-11-19 2014-11-19
US62/081,960 2014-11-19
JP2017525517A JP7023708B2 (ja) 2014-11-12 2015-11-09 阻害性キメラ抗原受容体
PCT/IB2015/058650 WO2016075612A1 (en) 2014-11-12 2015-11-09 Inhibitory chimeric antigen receptors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017525517A Division JP7023708B2 (ja) 2014-11-12 2015-11-09 阻害性キメラ抗原受容体

Publications (2)

Publication Number Publication Date
JP2022036976A JP2022036976A (ja) 2022-03-08
JP2022036976A5 true JP2022036976A5 (cg-RX-API-DMAC7.html) 2022-06-28

Family

ID=54695797

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017525517A Active JP7023708B2 (ja) 2014-11-12 2015-11-09 阻害性キメラ抗原受容体
JP2021188305A Pending JP2022036976A (ja) 2014-11-12 2021-11-19 阻害性キメラ抗原受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017525517A Active JP7023708B2 (ja) 2014-11-12 2015-11-09 阻害性キメラ抗原受容体

Country Status (6)

Country Link
US (3) US11072644B2 (cg-RX-API-DMAC7.html)
EP (1) EP3218394A1 (cg-RX-API-DMAC7.html)
JP (2) JP7023708B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015344769B2 (cg-RX-API-DMAC7.html)
CA (1) CA2967222C (cg-RX-API-DMAC7.html)
WO (1) WO2016075612A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6445447B2 (ja) * 2012-11-12 2018-12-26 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクRuprecht−Karls−Universitaet Heidelberg Hbv及び/又はhdv感受性の細胞、細胞株及び非ヒト動物の開発
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CN113082201B (zh) 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
WO2017205747A1 (en) * 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
MX2019003462A (es) * 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
WO2018064921A1 (en) * 2016-10-06 2018-04-12 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
WO2018104473A1 (en) * 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
PE20241587A1 (es) 2017-06-02 2024-08-01 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
PL3688155T3 (pl) 2017-09-28 2023-09-11 Immpact-Bio Ltd. Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar)
US20190338244A1 (en) * 2017-11-30 2019-11-07 New York Medical College Multipotent adult stem cells: characterization and use
IL326873A (en) * 2017-12-29 2026-04-01 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
BR112021006100A2 (pt) * 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
JP2022512594A (ja) 2018-10-05 2022-02-07 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体(car)の群
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
JP7646552B2 (ja) 2019-01-31 2025-03-17 ビーム セラピューティクス インク. 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
EP4017510A4 (en) * 2019-08-20 2023-11-22 Senti Biosciences, Inc. CHIMERIC INHIBITOR RECEPTOR
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
WO2021068068A1 (en) * 2019-10-08 2021-04-15 Provincial Health Services Authority Chimeric cytokine receptors
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
CN115298209A (zh) * 2020-02-20 2022-11-04 森迪生物科学公司 抑制性嵌合受体构造体
WO2021168317A1 (en) * 2020-02-20 2021-08-26 Senti Biosciences, Inc. Inhibitory chimeric receptor architectures
GB202004832D0 (en) * 2020-04-01 2020-05-13 Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
CN111607596A (zh) * 2020-05-27 2020-09-01 上海斯丹赛生物技术有限公司 修饰的pd-1及其在细胞治疗中的用途
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
US11433100B2 (en) 2020-08-20 2022-09-06 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
US20220090015A1 (en) * 2020-09-21 2022-03-24 A2 Biotherapeutics, Inc. Engineered immune cells with multiplex and localized activity
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CA3213040A1 (en) * 2021-03-22 2022-09-29 Michel Sadelain Cd38 chimeric co-stimulating receptor and uses thereof
WO2022204326A1 (en) * 2021-03-24 2022-09-29 The Regents Of The University Of California Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
JP2024520430A (ja) * 2021-05-26 2024-05-24 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 阻害性キメラ抗原受容体は養子細胞治療のオンターゲット・オフ腫瘍効果を防止する
CN115028682B (zh) * 2022-06-30 2025-06-06 合肥工业大学 一种来源于干腌火腿的增咸肽及制备方法
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
CN119506295B (zh) * 2025-01-21 2025-05-30 上海皓鸿生物医药科技有限公司 一种前列腺特异性膜抗原的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20050042664A1 (en) 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9307495B2 (en) 2011-09-12 2016-04-05 Apple Inc. Monitoring a battery in a portable electronic device
AU2014386824B2 (en) * 2013-03-15 2019-05-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
ES2769574T3 (es) * 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
US20170296623A1 (en) * 2014-12-17 2017-10-19 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
EP3262166A4 (en) * 2015-02-24 2018-08-15 The Regents of The University of California Binding-triggered transcriptional switches and methods of use thereof
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
MX2019003462A (es) * 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
WO2019089592A1 (en) * 2017-10-31 2019-05-09 The General Hospital Corporation Molecular switch-mediated control of engineered cells
WO2021173442A1 (en) * 2020-02-24 2021-09-02 The Regents Of The University Of California In-series synthetic receptor and-gate circuits for expression of a therapeutic payload by engineered cells

Similar Documents

Publication Publication Date Title
JP2022109975A5 (cg-RX-API-DMAC7.html)
Chen et al. Bispecific antibodies in cancer immunotherapy
Li et al. A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer
JP2021529559A5 (cg-RX-API-DMAC7.html)
JP2022548796A5 (cg-RX-API-DMAC7.html)
JP2024534417A5 (cg-RX-API-DMAC7.html)
JP2024023228A5 (cg-RX-API-DMAC7.html)
Hombach et al. T cell activation by recombinant FcεRI γ-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition
HRP20250135T1 (hr) Notch receptori sa zglobnom domenom
JP2024534471A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2021525731A5 (cg-RX-API-DMAC7.html)
JP2019537433A5 (cg-RX-API-DMAC7.html)
JP2019532625A5 (cg-RX-API-DMAC7.html)
JP2021520788A5 (cg-RX-API-DMAC7.html)
JP2023507729A5 (cg-RX-API-DMAC7.html)
JP2019531056A5 (cg-RX-API-DMAC7.html)
GB2607452A (en) Anti-TCR antibody molecules and uses thereof
JP2013519379A5 (cg-RX-API-DMAC7.html)
CN104592392B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
HRP20220767T1 (hr) Liječenje raka uporabom humaniziranog kimernog receptora antigena anti-cd19
JP2020513828A5 (cg-RX-API-DMAC7.html)
JP2022524906A (ja) 細胞免疫療法の組み合わせ
JP2024511423A5 (cg-RX-API-DMAC7.html)
Stamova et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses